We recently published 10 Market Winners With Stunning Gains. Immunitybio Inc. (NASDAQ:IBRX) was one of the best performers on Wednesday. ImmunityBio soared to a new 52-week high on Wednesday, as investors gobbled up shares over an aggressive international expansion for its therapy, Anktiva. At intra-day trading, the stock climbed to its highest price of $8.68 before trimming gains to end the day just up by 41.86 percent at $8.54 apiece. In a statement, Immunitybio Inc. (NASDAQ:IBRX) said that the Europ ...

ImmunityBio (NASDAQ:IBRX), which develops immunotherapies and vaccines for cancers and infectious diseases, closed Wednesday at $8.54, up 41.86%. The stock jumped after the European Commission granted conditional marketing authorization for Anktiva to treat bladder cancer. Trading volume reached 78.5 million shares, about 178% above its three-month average of 28.2 million shares. ImmunityBio IPO'd in 2015 and has fallen 75% since going public. How the markets moved today The S&P 500 rose 0.53% to finish ...

Wednesday's trading session is proving to be a thrilling one for ImmunityBio (NASDAQ: IBRX) shareholders. As of 1:50 p.m. ET today the biopharma stock is up an incredible 33.1%. The reason? Unsurprisingly, an approval of its breadwinning drug in another huge market. Approved... again ImmunityBio's oncology drug Anktiva had already been approved as a treatment for certain forms of bladder cancer as early as 2024, for the record, when the United States' FDA gave the immunotherapy the green light. The Unite ...

ImmunityBio, Inc. ( IBRX ) stock has been on a very bullish run. The investor confidence comes from the potential of a chemo‑free immunotherapy platform, which is led by Anktiva. The short idea here is that Anktiva is an IL‑15 superagonist that fuelsI hold a Master’s degree in Cell Biology and began my career working for several years as a lab technician in a drug discovery clinic, where I gained extensive hands-on experience in cell culture, assay development, and therapeutic research. That scientific foun ...

分组1 - ImmunityBio, Inc. (IBRX) stock is experiencing a bullish trend driven by investor confidence in its chemo-free immunotherapy platform led by Anktiva [1] - Anktiva is identified as an IL-15 superagonist that enhances immune response, contributing to the positive outlook for the company's stock [1] 分组2 - The company focuses on innovative biotechnology solutions, particularly through unique mechanisms of action and first-in-class therapies [1] - The analysis emphasizes the importance of evaluating the scientific basis of drug candidates, competitive landscape, clinical trial design, and market opportunities [1]

Core Insights - ImmunityBio Inc. (NASDAQ:IBRX) experienced a significant share price increase of 14.55%, closing at $6.93, as investors prepared for its upcoming participation in the American Society of Clinical Oncology (ASCO) event [1][6]. Company Developments - ImmunityBio is set to participate in the 2026 ASCO Genitourinary Cancers Symposium from February 26 to 28 in San Francisco, focusing on research and treatments for genitourinary cancers [2]. - Earlier this year, ImmunityBio reported a remarkable 700% increase in sales from its cancer therapy Anktiva and announced plans to expand operations into Saudi Arabia, where it will sell Anktiva for lung cancer patients following FDA approval [3]. Market Context - Lung cancer is a prevalent cancer type in Saudi Arabia, indicating a significant market opportunity for ImmunityBio's products [3].

Industry Overview - The global oncology market is undergoing rapid transformation due to increasing cancer incidence, demographic changes, and scientific advancements, with an estimated 2.1 million new cancer diagnoses and over 626,000 cancer-related deaths expected in the U.S. in 2026 [2] - Lifestyle-related risk factors and demographic shifts are contributing to a rise in cancer prevalence, leading to sustained growth in oncology healthcare spending [2] Innovation in Cancer Treatment - Advances in immunotherapies, targeted medicines, and personalized vaccines are reshaping cancer treatment, moving beyond traditional chemotherapy and radiation [3] - Immune-based approaches, such as checkpoint inhibitors and CAR-T therapies, utilize the immune system to target tumors, while targeted therapies focus on specific molecular and genetic disease drivers [3] - Technologies like genomic sequencing and AI are enhancing biomarker discovery and patient stratification, leading to earlier diagnoses and improved survival rates across various cancer types [4] Pharmaceutical Investment - Major pharmaceutical companies, including Novartis, AstraZeneca, and Pfizer, are investing heavily in oncology pipelines, developing new therapies such as antibody-drug conjugates and next-generation immuno-oncology treatments [5] - Smaller biotech firms are also crucial in driving innovation through partnerships, licensing deals, and acquisitions [5] Market Resilience - The oncology sector is viewed as one of the most resilient and attractive segments of the global healthcare market for long-term investors, supported by ongoing innovation and favorable reimbursement trends [6] Company Highlights - **ImmunityBio**: Its lead drug, Anktiva, approved in April 2024, generated $113 million in preliminary sales in 2025, with a 750% increase in volumes. The drug is under review in the EU and is being evaluated for expanded use in various cancers [8][9] - **Arcus Biosciences**: Developing casdatifan, a potential best-in-class HIF-2a inhibitor for treating clear cell renal cell carcinoma, with a market opportunity of over $5 billion. Multiple data readouts are expected in 2026 [10] - **Allogene Therapeutics**: Focused on genetically engineered T-cell therapies, with lead candidate cema-cel in a pivotal phase II study for large B-cell lymphoma. Another candidate, ALLO-316, shows early anti-tumor activity in advanced renal cell carcinoma [12][13]

Core Insights - ImmunityBio Inc. (NASDAQ:IBRX) has experienced a significant decline of 4.19% on Tuesday, marking the third consecutive day of losses as investors take profits after a 14-day rally [1] - The stock surged by 271% in January due to positive developments, including strong clinical trial results and a 700% increase in sales from its therapy Anktiva [2] - The company is preparing to announce detailed results from its QUILT-3.078 Phase 2 study, which evaluates a chemotherapy-free immunotherapy regimen for patients with recurrent or progressive glioblastoma [3][4] Financial Performance - The recent decline follows a substantial increase in stock value, with a notable 14-day gain prior to the downturn [1] - The treatment under study has shown a manageable safety profile, with 19 out of 23 enrolled patients remaining alive, and four deaths reported [5] Market Position - ImmunityBio's expansion into international markets and the strong performance of its therapy Anktiva have contributed to its recent stock price surge [2] - The company is positioned in a competitive landscape, with some analysts suggesting that other AI stocks may offer better investment opportunities [6]

Company Overview - ImmunityBio (NASDAQ:IBRX) closed at $6.45, down 12.13%, but has seen a significant increase of 63.29% in the past five days and 207.14% in the past month [1] - The company has experienced a trading volume of 74.6 million shares, which is 238% above its three-month average of 22.1 million shares [1] - Since its IPO in 2015, ImmunityBio's stock has fallen 83% [1] Market Context - The broader markets were steady, with the S&P 500 edging up 0.03% and the Nasdaq Composite rising 0.28% [2] - Biotechnology and pharmaceuticals peers, including Merck and BioNTech, experienced slight losses, indicating ongoing volatility in the sector [2] Recent Developments - ImmunityBio's recent losses may be attributed to profit-taking after a significant rise in stock price [3] - The company has made progress with the FDA regarding its Anktiva bladder cancer therapy application, which is set to be resubmitted [3] - The Saudi FDA has granted approval for Anktiva [3] Financial Performance - The firm's full-year results exceeded analyst expectations, with a net profit of $113 million, representing a 700% increase year-on-year [4] - In a recent update, it was reported that 19 out of 23 patients with progressive glioblastoma receiving Anktiva are still alive, although the median overall survival has not yet been reached [4] Analyst Sentiment - Several analysts, including H.C. Wainwright, have raised their price targets for ImmunityBio's stock [5] - Exits from short sellers have positively impacted the company, with reported paper losses of around $492 million for short sellers [5]

Core Insights - ImmunityBio's shares increased by 17.4% following a meeting with FDA officials to discuss the regulatory path for Anktiva in treating BCG-unresponsive non-muscle invasive bladder cancer (NMIBC) with papillary tumors [1][6] - The company plans to resubmit its supplemental biologics license application (sBLA) for Anktiva plus Bacillus Calmette-Guérin (BCG) after addressing FDA's requests for additional information [4][10] Company Developments - Anktiva is already approved in the U.S., EU, and UK for treating adults with BCG-unresponsive NMIBC with carcinoma in situ (CIS) [2] - The recent FDA meeting allowed ImmunityBio to present over five years of follow-up data supporting the papillary indication, demonstrating a safety profile consistent with the approved CIS indication [3][5] - The company has completed the requested analyses and plans to submit the sBLA package within a month, without the need for a new clinical study [4][6] Clinical Evidence - The proposed sBLA resubmission is supported by long-term data from the phase II/III QUILT-3.032 study, which showed a 12-month disease-free survival rate of 58.2% in patients with high-grade papillary-only disease [7] - Disease-specific survival reached 96% at 36 months, with progression-free survival at 94.9% at 12 months and 83.1% at 36 months, indicating sustained disease control [8] - Anktiva demonstrated a bladder-sparing benefit, with cystectomy-free survival rates of 92.2% at 12 months and 81.8% at 36 months, allowing over 80% of patients to avoid radical surgery [8][10] Market Context - High-grade papillary NMIBC that does not respond to BCG represents a significant unmet medical need, as current standard treatment involves radical cystectomy, which has considerable morbidity [9] - ImmunityBio aims to provide a bladder-sparing alternative, potentially reshaping the treatment landscape for these patients if Anktiva is approved [10][12]